SPRO Fail-to-Deliver
Spero Therapeutics, Inc. (SPRO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $66.6M, listed on NASDAQ, employing roughly 25 people, carrying a beta of 1.50 to the broader market. Spero Therapeutics, Inc. Led by Esther Rajavelu, public since 2017-11-02.
No records carrying symbol SPRO appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 26, 2026 through September 14, 2026.
Most recent fail-to-deliver in our records: August 25, 2026.
Frequently asked SPRO fail-to-deliver questions
- Has SPRO had any fails-to-deliver recently?
- No records carrying symbol SPRO appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 26, 2026 through September 14, 2026. Most recent fail-to-deliver in our records: August 25, 2026. The SEC publishes the first half of each month at the month's end and the second half around the 15th of the next month, so this check covers settlement dates through September 14, 2026.
- What does it mean when SPRO is absent from the SEC fails-to-deliver data?
- The SEC's files give the aggregate net balance of shares that failed to be delivered in NSCC's Continuous Net Settlement system, by security and settlement date. Since September 16, 2008 a security has a record for every settlement date on which that balance was above zero, and none when it was zero. This check is by symbol, so a fail reported only under a CUSIP or a former symbol is not counted.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
Learn how fails-to-deliver is reported and how to read the data →